1. Aceti, A.; Pasquazzi, C.; Zechini, B.; de Bac, C.; Group, L.

Hepatotoxicity development
during antiretroviral therapy containing protease inhibitors in patients with HIV: The role
of hepatitis B and C virus infection. J. Acquir. Immune Defic. Syndr. 2002, 29, 41–48.
2. Adela Țurcanu, Vlada-Tatiana Dumbrava, Maria Cojocaru, I.Graur. Maladii Hepatice
Drog-Induse. Volum de rezumate. 24-27 octombrie 2007, Chișinău, 53-56.
3. Aithal, G.P. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: Current
role in clinical practice. Liver Int. 2015, 35, 1801–1808.
4. Aithal, G.P.; Watkins, P.B.; Andrade, R.J.; Larrey, D.; Molokhia, M.; Takikawa, H.;
Hunt, C.M.; Wilke, R.A.; Avigan, M.; Kaplowitz, N.; et al. Case definition and
phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 2011, 89,
806–815.
5. Aithal, G.P. Hepatotoxicity related to antirheumatic drugs.
Nat.Rev.Rheumatol.2011,7,139–150.
6. Aleo, M.D.; Luo, Y.; Swiss, R.; Bonin, P.D.; Potter, D.M.; Will, Y. Human drug-induced
liver injury severity is highly associated with dual inhibition of liver mitochondrial
function and bile salt export pump. Hepatology 2014, 60, 1015–1022.
7. Amital,H.;Arnson,Y.;Chodick,G.;Shalev,V.Hepatotoxicityratesdonotdifferinpatientswithr
heumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford)
2009, 48, 1107–1110.
8. Andrade, R.J.; López-Ortega, S.; López-Vega, M.C.; Robles, M.; Cueto, I.; Lucena, M.I.
Idiosyncratic drug hepatotoxicity: A 2008 update. Expert Rev. Clin. Pharmacol. 2008, 1,
261–276.
9. Andrade, R.J.; Lucena, M.I.; Fernández, M.C.; Pelaez, G.; Pachkoria, K.; Garciá -Ruiz,
E.; Garciá -Muñoz, B.; González-Grande, R.; Pizarro, A.; Durán, J.A.; et al. Drug-induced
liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-
year period. Gastroenterology 2005, 129, 512–521.
10. Andrade, R.J.; Robles, M.; Fernández-Castañer, A.; López-Ortega, S.; López-Vega,
M.C.; Lucena, M.I. Assessment of drug-induced hepatotoxicity in clinical practice: A
challenge for gastroenterologists. World J. Gastroenterol. 2007, 13, 329–340.
11. Andrade, R.J.; Robles, M.; Ulzurrun, E.; Lucena, M.I. Drug-induced liver injury: Insights
from genetic studies. Pharmacogenomics 2009, 10, 1467–1487.
12. Andrade, R.J. Reducing Risk of Severe Liver Injury in Patients Treated With Isoniazid.
Clin.Gastroenterol.Hepatol. 2015, 13, 1683–1685.
13. Anon, ed. – Tylenol professional product information. McNeil Consumer Healthcare,
Division of McNEIL-PPC, Inc, Fort Washington, PA, 19034, USA; 2010
14. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, et al. Mechanistic
biomarkers provide early and sensitive detection of acetaminophen-induced acute liver
injury at first presentation to hospital. Hepatology. 2013; 58:777–87.
15. Antoine DJ, Jenkins RE, Dear JW, Williams DP, McGill MR, Sharpe MR, et al.
Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell
death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol. 2012;
56:1070–9.
16. Antoine DJ, Williams DP, Kipar A, Jenkins RE, Regan SL, Sathish JG, et al. High-
mobility group box-1 protein and keratin-18, circulating serum proteins informative of
acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci. 2009; 112:521–31.
17. Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev.
2007;25(1):76–97.
18. Arthur C. Guyton, John E. Hall. Tratat de fiziologie a omului, ed.11. Editura Medicală
Callisto, București, 2007, 859-864.
19. Bajt ML, Cover C, Lemasters JJ, Jaeschke H. Nuclear translocation of endonuclease G
and apoptosis-inducing factor during acetaminophen-induced liver cell injury. Toxicol
Sci. 2006; 94:217–25.
20. Bauman, J.N.; Kelly, J.M.; Tripathy, S.; Zhao, S.X.; Lam, W.W.; Kalgutkar, A.S.;
Obach, R.S. Can in vitro metabolism-dependent covalent binding data distinguish
hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver
S-9 fraction. Chem. Res. Toxicol. 2009, 22, 332–340.
21. Bessone Fernando. Non-steroidal ant-inflammatory drugs: What is the actual risk of liver
damage? In: World J. Gastroenterol.,2010, Dec.7; nr.16(45).p-5651-5661.
22. Bhattacharyya S, Pence L, Beger R, Chaudhuri S, McCullough S, Yan K, et al.
Acylcarnitine profiles in acetaminophen toxicity in the mouse: comparison to toxicity,
metabolism and hepatocyte regeneration. Metabolites. 2013; 3:606–22.
23. Bhattacharyya S, Yan K, Pence L, Simpson PM, Gill P, Letzig LG, et al. Targeted liquid
chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen
toxicity in children. Biomark Med. 2014; 8:147–59.
24. Bjornsson, E.S.; Bergmann, O.M.; Bjornsson, H.K.; Kvaran, R.B.; Olafsson, S.
Incidence, presentation, and outcomes in patients with drug-induced liver injury in the
general population of Iceland. Gastroenterology 2013, 144, 1419–1425.
25. Bjornsson, E.S.; Jonasson, J.G. Drug-induced cholestasis. Clin. Liver Dis. 2013, 17, 191–
209.
26. Björnsson,E.; Jacobsen,E.I.; Kalaitzakis, E. Hepatotoxicity associated with statins:
Reports of idiosyncratic liver injury post-marketing. J. Hepatol. 2012, 56, 374–380.
27. Boelsterli, U.A.; Lim, P.L. Mitochondrial abnormalities—A link to idiosyncratic drug
hepatotoxicity? Toxicol. Appl. Pharmacol. 2007, 220, 92–107.
28. Burtis, C.A., and Ashwood, E.R., eds. (1999) Tietz Textbook of Clinical Chemistry. 3rd
edition. Saunders, Philadelphia.
29. Caravati E.M. – Unintentional acetaminophen ingestion in children and the potential for
hepatotoxicity. J Toxicol Clin Toxicol 2000.
30. Carrascosa, M.F.; Salcines-Caviedes, J.R.; Lucena, M.I.; Andrade, R.J. Acute liver
failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic
hepatotoxicity? J. Hepatol. 2015, 62, 751–752.
31. Chalasani, N.; Bonkovsky, H.L.; Fontana, R.; Lee, W.; Stolz, A.; Talwalkar, J.; Reddy,
K.R.; Watkins, P.B.; Navarro, V.; Barnhart, H.; et al. Features and Outcomes of 899
Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.
Gastroenterology 2015, 148, 1340–1352.
32. Chen C, Krausz KW, Shah YM, Idle JR, Gonzalez FJ. Serum metabolomics reveals
irreversible inhibition of fatty acid beta-oxidation through the suppression of PPAR alpha
activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem
Res Toxicol. 2009; 22:699–707.
33. Chen, M.; Suzuki, A.; Borlak, J.; Andrade, R.J.; Lucena, M.I. Drug-induced liver injury:
Interactions between drug properties and host factors. J. Hepatol. 2015, 63, 503–514.
34. Chen, M.; Tung, C.W.; Shi, Q.; Guo, L.; Shi, L.; Fang, H.; Borlak, J.; Tong, W. A testing
strategy to predict risk for drug-induced liver injury in humans using high-content screen
assays and the “rule-of-two” model. Arch. Toxicol. 2014, 88, 1439–1449.
35. Dan L. Longo, Anthony S. Fauci. Harrison - Gastroenterologie si Hapatologie. Ed.
ALL, București, 2017. 385-396.
36. Dargan P.I., Ladhani S., Jones A.L. – Measuring plasma paracetamol concentrations in
all patients with drug overdose or altered consciousness: does it change outcome? Emerg
Med J 2001; 18(3):178-82.
37. Dart R.C., Bailey E. – Does therapeutic use of acetaminophen cause acute liver failure?
Pharmacotherapy 2007; 27(9):1219-30.
38. Dart R.C., Erdman A.R., Olson K.R., et al. – Acetaminophen poisoning: an evidence
based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2006;
44(1):1-18.
39. Dawson, S.; Stahl, S.; Paul, N.; Barber, J.; Kenna, J.G. In vitro inhibition of the bile salt
export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug
Metab. Dispos. 2012, 40, 130–138.
40. De Abajo, F.J.; Montero, D.; Madurga, M.; García Rodríguez, L.A. Acute and clinically
relevant drug-induced liver injury: A population based case-control study. Br. J. Clin.
Pharmacol. 2004, 58, 71–80.
41. Delemos, A.S.; Foureau, D.M.; Jacobs, C.; Ahrens, W.; Russo, M.W.; Bonkovsky, H.L.
Drug-induced liver injury with autoimmune features. Semin. Liver Dis. 2014, 34, 194–
204.
42. Dubin PH, Yuan H, Devine RK, Hynan LS, Jain MK, Lee WM, et al. Micro-RNA-122
levels in acute liver failure and chronic hepatitis C. J Med Virol. 2014; 86:1507–14.
43. Dumitraşcu Diana. Leziunile hepatice induse de medicamente. Tratat de Gastrologie
clinică. Vol II. Sub red. Prof. dr. Mircea Grigorescu, prof. Oliviu Pascu. Bucureş ti:
Editura Tehnică, 1997;282-297.
44. Dykens, J.A.; Will, Y. The significance of mitochondrial toxicity testing in drug
development. Drug Discov. Today 2007, 12, 777–785.
45. FDA (2009) FDA guidance for industry. Drug-induced liver injury. Premarketing clinical
evaluation.
46. Felker, D.; Lynn, A.; Wang, S.; Johnson, D.E. Evidence for a potential protective effect
of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.
Expert Rev. Clin. Pharmacol. 2014, 7, 211–218.
47. Fisher, K.; Vuppalanchi, R.; Saxena, R. Drug-Induced Liver Injury. Arch. Pathol. Lab.
Med. 2015, 139, 876–887.
48. Fontana Robert J.Pathogenesis of Idiosycratic Drug-Induced Liver Injury and Clinical
Perspectives. In: Gastroenterology, 2014, Apr.; nr. 146(4), p.914-928.
49. Fontana, R.J.; Hayashi, P.H.; Gu, J.; Reddy, K.R.; Barnhart, H.; Watkins, P.B.; Serrano,
J.; Lee, W.M.; Chalasani, N.; Stolz, A.; et al. Idiosyncratic drug-induced liver injury is
associated with substantial morbidity and mortality within 6 months from onset.
Gastroenterology 2014, 147, 96–108.
50. Fontana, R.J.; Watkins, P.B.; Bonkovsky, H.L.; Chalasani, N.; Davern, T.; Serrano, J.;
Rochon, J.; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN)
prospective study: Rationale, design and conduct. Drug Saf. 2009, 32, 55–68.
51. Fountain, F.F.; Tolley, E.; Chrisman, C.R.; Self, T.H. Isoniazid hepatotoxicity associated
with treatment of latent tuberculosis infection: A 7-year evaluation from a public health
tuberculosis clinic. Chest 2005, 128, 116–123.
52. Furihata T, Aizawa T, Koibuchi A, Zhu M, Yamasaki Y, Shibuya M, et al.
Characterization of release profile of ornithine carbamoyltransferase from primary rat
hepatocytes treated with hepatotoxic drugs: Implications for its unique potential as a
drug-induced liver injury biomarker. Drug Metab Pharmacokinet. 2016; 31:102–5.
53. Geier, A.; Wagner, M.; Dietrich, C.G.; Trauner, M. Principles of hepatic organic anion
transporter regulation during cholestasis, inflammation and liver regeneration. Biochim.
Biophys. Acta 2007, 1773, 283–308.
54. Gelotte C.K., Auiler J.F., Lynch J.M., et al. – Disposition of acetaminophen at 4, 6, and 8
g/day for 3 days in healthy young adults. Clin Pharmacol Ther 2007; 81(6):840-8 ).
55. Goodman, Z.D. Drug hepatotoxicity. Clin. Liver Dis. 2002, 6, 381–397.
56. H. Zimmerman. Drug Hepatotoxicity. (2nd edition). Lippincott, Philadelphia, 1999.
57. Han, D.; Dara, L.; Win, S.; Than, T.A.; Yuan, L.; Abbasi, S.Q.; Liu, Z.X.; Kaplowitz, N.
Regulation of drug-induced liver injury by signal transduction pathways: Critical role of
mitochondria. Trends Pharmacol. Sci. 2013, 34, 243–253.
58. Heubi, J.E.; Partin, J.C.; Partin, J.S.; Schubert, W.K. Reye’s syndrome: Current concepts.
Hepatology 1987, 7, 155–164.
59. Hodgman M.J., Horn J.F., Stork C.M., et al. – Profound metabolic acidosis and
oxoprolinuria in an adult. J Med Toxicol 2007; 3(3):119-24
60. Holt M, Ju C. Drug-induced liver injury. Handb Exp Pharmacol. 2010;196:3–27.
61. HoltMP,JuC.Mechanismsofdrug-inducedliverinjury.AAPSJ.2006; 8(1):E48–E54.
62. Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility
to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol.
2007;3(1):1–8.
63. Hughes, J.D.; Blagg, J.; Price, D.A.; Bailey, S.; Decrescenzo, G.A.; Devraj, R.V.;
Ellsworth, E.; Fobian, Y.M.; Gibbs, M.E.; Gilles, R.W.; et al. Physiochemical drug
properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett.
2008, 18, 4872–4875.
64. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview.
Expert Opin Drug Saf. 2007;6(6):673–684.
65. Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death
mechanisms in drug-induced liver injury: lessons learned from acetaminophen
hepatotoxicity. Drug Metab Rev. 2012;44(1):88–106.
66. Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death
mechanisms in drug-induced liver injury: lessons learned from acetaminophen
hepatotoxicity. Drug Metab Rev. 2012; 44:88–106.
67. Jones D.P., Lemasters J.J., Han D., et al. – Mechanisms of pathogenesis in drug
hepatotoxicity putting the stress on mitochondria. Mol Interv 2010; 10(2):98-111).
68. Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug
Metab Rev. 2012;44(1):107–115.
69. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004; 38 Suppl 2:S44–S48.
70. Kaplowitz N., Shinohara M., Liu Z.X., et al. – How to protect against acetaminophen:
don’t ask for JUNK. Gastroenterology 2008; 135(4):1047-51).
71. Kaplowitz Neil and Laurie D. DeLeve. Drug-Induced Liver Disease. Third Edition, 2013,
ISBN:978-0-12-38-7817-5. 6.
72. Kleiner, D.E.; Chalasani, N.P.; Lee, W.M.; Fontana, R.J.; Bonkovsky, H.L.; Watkins,
P.B.; Hayashi, P.H.; Davern, T.J.; Navarro, V.; Reddy, R.; et al. Hepatic histological
findings in suspected drug-induced liver injury: Systematic evaluation and clinical
associations. Hepatology 2014, 59, 661–670.
73. Köck, K.; Ferslew, B.C.; Netterberg, I.; Yang, K.; Urban, T.J.; Swaan, P.W.; Stewart,
P.W.; Brouwer, K.L. Risk factors for development of cholestatic drug-induced liver
injury: Inhibition of hepatic basolateral bile acid transporters multidrug resistance-
associated proteins 3 and 4. Drug Metab. Dispos. 2014, 42, 665–674.
74. Labbe, G.; Pessayre, D.; Fromenty, B. Drug-induced liver injury through mitochondrial
dysfunction: Mechanisms and detection during preclinical safety studies. Fundam. Clin.
Pharmacol. 2008, 22, 335–353.
75. Lammert, C.; Bjornsson, E.; Niklasson, A.; Chalasani, N. Oral medications with
significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology
2010, 51, 615–620.
76. Lammert, C.; Einarsson, S.; Saha, C.; Niklasson, A.; Bjornsson, E.; Chalasani, N.
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver
injury: Search for signals. Hepatology 2008, 47, 2003–2009.
77. Larrey, D. Drug-induced liver diseases. J. Hepatol. 2000, 32, 77–88.
78. Larrey, D. Epidemiology and individual susceptibility to adverse drug reactions affecting
the liver. Semin. Liver Dis. 2002, 22, 145–155.
79. Leeson, P.D.; Springthorpe, B. The influence of drug-like concepts on decision-making
in medicinal chemistry. Nat. Rev. Drug Discov. 2007, 6, 881–890.
80. Leone, A.; Nie, A.; Brandon Parker, J.; Sawant, S.; Piechta, L.A.; Kelley, M.F.; Maark
Kao, L.; Jim Proctor, S.; Verheyen, G.; Johnson, M.D.; et al. Oxidative stress/reactive
metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants.
Toxicol. Appl. Pharmacol. 2014, 275, 189–97.
81. Liao K., Karlson E. Rheumatoid Arthritis in Rheumatology. 5th edition, Mosby-Elsevier,
2011, p.823-971.
82. Liu, Y.M.; Cheng, Y.J.; Li, Y.L.; Liu, C.E.; Hsu, W.H. Antituberculosis treatment and
hepatotoxicity in patients with chronic viral hepatitis. Lung 2014, 192, 205–210.
83. Lomtadze, N.; Kupreishvili, L.; Salakaia, A.; Vashakidze, S.; Sharvadze, L.; Kempker,
R.R.; Magee, M.J.; del Rio, C.; Blumberg, H.M. Hepatitis C virus co-infection increases
the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary
tuberculosis. PLoS ONE 2013, 8, e83892.
84. Long JP, Fitzgerald O, Maurer BJ. Hepatotoxicity following treatment with perhexiline
maleate. Ir Med J. 1980;73(7):275–276.
85. Lucena, M.I.; Andrade, R.J.; Kaplowitz, N.; Garciá -Cortés, M.; Fernández, M.C.;
Romero-Gómez, M.; Bruguera, M.; Hallal, H.; Robles-Diá z, M.; Rodriǵ uez-González,
J.F.; et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: The
influence of age and sex. Hepatology 2009, 49, 2001–2009.
86. Lucena, M.I.; García-Martín, E.; Andrade, R.J.; Martínez, C.; Stephens, C.; Ruiz, J.D.;
Ulzurrun, E.; Fernández, M.C.; Romero-Gómez, M.; Castiella, A.; et al. Mitochondrial
superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver
injury. Hepatology 2010, 52, 303–312.
87. Mark H. Beers, Robert Berkow; coord.trad.:Rodica Chirculescu. Manualul Merck de
diagnostic și tratament. București, BIC ALL, 2002, 2556-2566.
88. Martinez, M.A.; Vuppalanchi, R.; Fontana, R.J.; Stolz, A.; Kleiner, D.E.; Hayashi, P.H.;
Gu, J.; Hoofnagle, J.H.; Chalasani, N. Clinical and histologic features of azithromycin-
induced liver injury. Clin. Gastroenterol. Hepatol. 2015, 13, 369–376.
89. McGill MR, Cao M, Svetlov A, Sharpe MR, Williams CD, Curry SC, et al.
Argininosuccinate synthetase as a plasma biomarker of liver injury after acetaminophen
overdose in rodents and humans. Biomarkers. 2014; 19:222–30.
90. McGill MR, Jaeschke H. Mechanistic biomarkers in acetaminophen-induced
hepatotoxicity and acute liver failure: from preclinical models to patients. Expert Opin
Drug Metab Toxicol. 2014; 10:1005–17.
91. McGill MR, Li F, Sharpe MR, Williams CD, Curry SC, Ma X, et al. Circulating
acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose
in mice and humans. Arch Toxicol. 2014; 88:391–401.
92. McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, Jaeschke H. The mechanism
underlying acetaminophen-induced hepatotoxicity in humans and mice involves
 mitochondrial damage and nuclear DNA fragmentation. J Clin Invest. 2012; 122:1574–
83.
93. McGill MR, Staggs VS, Sharpe MR, Lee WM, Jaeschke H. Acute Liver Failure Study G.
Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in
acetaminophen overdose patients with poor outcome. Hepatology. 2014; 60:1336–45.
94. Medina-Cáliz,I.;Garcia-Muñoz,B.;RoblesDiaz,M.;Stephens,C.;González-
Jiménez,A.;Garciá -Cortés,M.; Ortega, A.; Hidalgo, R.; Fernández, M.C.; Romero-
Gómez, M.; et al. Risk factors for chronicity in idiosyncratic drug-induced liver injury
(DILI). Hepatology 2014, 60 (Suppl. 4), 139A.
95. Mitchell, S.J.; Hilmer, S.N. Drug-induced liver injury in older adults. Ther. Adv. Drug
Saf. 2010, 1, 65–77.
96. Mohler C.R., Nordt S.P., Williams S.R. et al. – Prospective evaluation of mild to
moderate pediatric acetaminophen exposures. Ann Emerg Med 2000; 35(3):239-44)
97. Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N. Characteristics of
idiosyncratic drug-induced liver injury in children: results from the DILIN prospective
study. J Pediatr Gastroenterol Nutr. 2011;53(2):182–189.
98. Morgan, R.E.; Trauner, M.; van Staden, C.J.; Lee, P.H.; Ramachandran, B.; Eschenberg,
M.; Afshari, C.A.; Qualls, C.W., Jr.; Lightfoot-Dunn, R.; Hamadeh, H.K. Interference
with bile salt export pump function is a susceptibility factor for human liver injury in
drug development. Toxicol. Sci. 2010, 118, 485–500.
99. Morgan, R.E.; van Staden, C.J.; Chen, Y.; Kalyanaraman, N.; Kalanzi, J.; Dunn, R.T.,
2nd.; Afshari, C.A.; Hamadeh, H.K. A multifactorial approach to hepatobiliary
transporter assessment enables improved therapeutic compound development. Toxicol.
Sci. 2013, 136, 216–241.
100. Murayama H, Ikemoto M, Fukuda Y, Nagata A. Superiority of serum type-I
arginase and ornithine carbamyltransferase in the detection of toxicant-induced acute
hepatic injury in rats. Clin Chim Acta. 2008; 391:31–5.
101. Nelson SD. Molecular mechanisms of the hepatotoxicity caused by
acetaminophen. Semin Liver Dis. 1990;10(4):267–278.

102. Niţ escu Gabriela Vioreta. Afectarea hepatică ş i renală în intoxicaţ iile acute
medicamentoase la copil. Protocoale terapeutice. Rezumat al tezei de doctorat. Bucureş ti,
2007.
103. Njoku DB. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis
of experimental drug-induced liver injury: a review. Expert Opin Drug Metab Toxicol.
2010;6(5):519–531.
104. Obach, R.S.; Kalgutkar, A.S.; Soglia, J.R.; Zhao, S.X. Can in vitro metabolism-
dependent covalent binding data in liver microsomes distinguish hepatotoxic from
nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance
and daily dose. Chem. Res. Toxicol. 2008, 21, 1814–1822.
105. Orman, E.S.; Conjeevaram, H.S.; Vuppalanchi, R.; Freston, J.W.; Rochon, J.;
Kleiner, D.E.; Hayashi, P.H.; DILIN Research Group. Clinical and histopathologic
features of fluoroquinolone-induced liver injury. Clin. Gastroenterol. Hepatol. 2011, 9,
517–523.
106. Ostapowicz, G.; Fontana, R.J.; Schiødt, F.V.; Larson, A.; Davern, T.J.; Han, S.H.;
McCashland, T.M.; Shakil, A.O.; Hay, H.E.; Hynan, L.; et al. Results of a prospective
study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern.
Med. 2002, 137, 947–954.
107. Ozer, J., Ratner, M., Shaw, M., Bailey, W., and Schomaker, S. (2008) The current
state of serum biomarkers of hepatotoxicity. Toxicology 245: 194205.
108. Park, B.K.; Laverty, H.; Srivastava, A.; Antoine, D.J.; Naisbitt, D.; Williams,
D.P. Drug bioactivation and protein adduct formation in the pathogenesis of drug-
induced toxicity. Chem. Biol. Interact. 2011, 192, 30–36.
109. Pérez, L.M.; Milkiewicz, P.; Elias, E.; Coleman, R.; Sánchez Pozzi, E.J.; Roma,
M.G. Oxidative stress induces internalization of the bile salt export pump, Bsep, and bile
salt secretory failure in isolated rat hepatocyte couplets: A role for protein kinase C and
prevention by protein kinase A. Toxicol. Sci. 2006, 91, 150–158.
110. Pollak PT, Sharma AD, Carruthers SG. Relation of amiodarone hepatic and
pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am
J Cardiol. 1990;65(18):1185–1191.
111. Porceddu, M.; Buron, N.; Roussel, C.; Labbe, G.; Fromenty, B.; Borgne-Sanchez,
A. Prediction of liver injury induced by chemicals in human with a multiparametric assay
on isolated mouse liver mitochondria. Toxicol. Sci. 2012, 129, 332–345.
112. Prescott L.F. – Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000;
49(4):291-301 .
Rumack B.H. – Acetaminophen hepatotoxicity: the first 35 years. J
Toxicol Clin Toxicol 2002; 40(1):3-20).
113. Pulkes, T.; Hanna, M.G. Human mitochondrial DNA diseases. Adv. Drug Deliv.
Rev. 2001, 49, 27–43.
114. Ramachandran, R., and Kakar, S. (2009) Histological patterns in drug-induced
liver disease. J Clin Pathol 62: 481492.Ramachandran, R.; Kakar, S. Histological patterns
in drug-induced liver disease. J. Clin. Pathol. 2009, 62, 481–492.
115. Reuben, A.; Koch, D.G.; Lee, W.M. Group ALFS. Drug-induced acute liver
failure: Results of a U.S. multicenter, prospective study. Hepatology 2010, 52, 2065–
2076.
116. Reust, C.E., and Hall, L. (2001) Clinical inquiries. What is the dif- ferential
diagnosis of an elevated alkaline phosphatase (AP) level in an otherwise asymptomatic
patient? J Fam Pract 50: 496497.
117. Robles-Diaz, M.; Garcia-Cortes, M.; Medina-Caliz, I.; González-Jiménez, A.;
González-Grande, R.; Navarro, J.M.; Castiella, A.; Zapata, E.M.; Romero-Gómez, M.;
Blanco, S.; et al. The value of serum aspartate aminotransferase and gamma-glutamyl
transpetidase as biomarkers in hepatotoxicity. Liver Int. 2015, 35, 2474–2482.
118. Servoss, J.C.; Kitch, D.W.; Andersen, J.W.; Reisler, R.B.; Chung, R.T.; Robbins,
G.K. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial
Group (1989–1999). J. Acquir. Immune Defic. Syndr. 2006, 43, 320–323.
119. Shi, Q., Hong, H., Senior, J., and Tong, W. (2010) Biomarkers for drug- induced
liver injury. Expert Rev Gastroenterol Hepatol 4: 225234.
120. Shu, C.C.; Lee, C.H.; Lee, M.C.; Wang, J.Y.; Yu, C.J.; Lee, L.N. Hepatotoxicity
due to first-line anti-tuberculosis drugs: A five-year experience in a Taiwan medical
centre. Int. J. Tuberc. Lung Dis 2013, 17, 934–939.
121. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, et al.
Circulating microRNAs as potential markers of human drug-induced liver injury.
Hepatology. 2011; 54:1767–76.
122. Stepan, A.F.; Walker, D.P.; Bauman, J.; Price, D.A.; Baillie, T.A.; Kalgutkar,
A.S.; Aleo, M.D. Structural alert/reactive metabolite concept as applied in medicinal
chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the
critical examination of trends in the top 200 drugs marketed in the United States. Chem.
Res. Toxicol. 2011, 24, 1345–1410.
123. Sulkowski, M.S.; Thomas, D.L.; Mehta, S.H.; Chaisson, R.E.; Moore, R.D.
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy:
Role of hepatitis C and B infections. Hepatology 2002, 35, 182–189.
124. T. Guţ ul, T. Covaliski, L. Cerempei, *L. Bocearova. Afecţ iunile toxico-
medicamentoase ale ficatului ş i rinichilor la copii. Curierul Medical nr.1(325) 2012
125. Temple A.R., Benson G.D., Zinsenheim J.R., et al. – Multicenter, randomized,
double blind, active- controlled, parallel-group trial of the long-term (6-12 months) safety
of acetaminophen in adult patients with osteoarthritis. Clin Ther 2006; 28(2):222-35).
126. Teschke,R.;Andrade,R.J.Drug-induced liver injury: Expanding our knowledge by
enlarging population analysis with prospective and scoring causality assessment.
Gastroenterology 2015, 148, 1271–1273.
127. Tilling,L.;Townsend,S.;David,J.Methotrexateandhepatictoxicityinrheumatoidarthr
itisandpsoriatic arthritis. Clin. Drug Investig. 2006, 26, 55–62.
128. Tsuda M, Taketani S, Sawamura T, Shiozaki Y, Tokunaga R, Sameshima Y.
Release of hepatic mitochondrial ornithine transcarbamylase into the circulation in D-
galactosamine-treated rats. Identification of serum ornithine transcarbamylase as the
intact form of the mitochondrial enzyme. J Biochem. 1985; 97:1391–9.
129. Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to
bench. Nat Rev Gastroenterol Hepatol. 2011;8(4):202–211. 15. McBurney RN, Hines
WM, Von Tungeln LS, et al. The liver toxicity biomarker study: phase I design and
preliminary results. Toxicol Pathol. 2009;37(1):52–64.
130. Uetrecht, J.P. New concepts in immunology relevant to idiosyncratic drug
reactions: The “danger hypothesis” and innate immune system. Chem. Res. Toxicol.
1999, 12, 387–395.
131. Uetrecht J. Immuno-allergic drug-induced liver injury in humans. Semin Liver
Dis. 2009;29(4):383–392.
132. Ulzurrun, E.; Stephens, C.; Crespo, E.; Ruiz-Cabello, F.; Ruiz-Nuñez, J.; Saenz-
López, P.; Moreno-Herrera, I.; Robles-Diaz, M.; Hallal, M.; Moreno-Planas, J.M.; et al.
Role of chemical structures and the 1331T>C bile salt export pump polymorphism in
idiosyncratic drug-induced liver injury. Liver Int. 2013, 33, 1378–1385.
133. Ungo, J.R.; Jones, D.; Ashkin, D.; Hollender, E.S.; Bernstein, D.; Albanese, A.P.;
Pitchenik, A.E. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C
virus and the human immunodeficiency virus. Am. J. Respir. Crit. Care Med. 1998, 157,
1871–1876.
134. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating
microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S
A. 2009; 106:4402–7.
135. Wang, J.Y.; Liu, C.H.; Hu, F.C.; Chang, H.C.; Liu, J.L.; Chen, J.M.; Yu, C.J.;
Lee, L.N.; Kao, J.H.; Yang, P.C. Risk factors of hepatitis during anti-tuberculous
treatment and implications of hepatitis virus load. J. Infect. 2011, 62, 448–455.
136. Ward J, Kanchagar C, Veksler-Lublinsky I, Lee RC, McGill MR, Jaeschke H, et
al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity
or ischemic hepatitis. Proc Natl Acad Sci U S A. 2014; 111:12169–74.
137. Waring W.S., Jamie H., Leggett G.E. – Delayed onset of acute renal failure after
significant paracetamol overdose: a case series. Hum Exp Toxicol 2010; 29(1):63-8
138. Watkins P.B., Kaplowitz N., Slattery J.T., et al. – Aminotransferase elevations in
healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial.
JAMA 2006; 296(1):87-93).
139. WebMD. Alanine Aminotransferase (ALT) (2013). , http://www.
webmd.com/digestive-disorders/alanine-aminotransferase-alt? page 5 2.
140. Weemhoff JL, Woolbright BL, Jenkins RE, McGill MR, Sharpe MR, Olson JC, et
al. Plasma biomarkers to study mechanisms of liver injury in patients with hypoxic
hepatitis. Liver Int. 2017; 37:377–84.
141. Weerasinghe SV, Jang YJ, Fontana RJ, Omary MB. Carbamoyl phosphate
synthetase-1 is a rapid turnover biomarker in mouse and human acute liver injury. Am J
Physiol Gastrointest Liver Physiol. 2014; 307:G355–64.
142. Weng, Z.; Wang, K.; Li, H.; Shi, Q. A comprehensive study of the association
between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975
oral medications. Oncotarget 2015, 6, 17031–17038.
143. Wintrobe ,M.M., and Greer, J.P. eds (2009) Wintrobe’s Clinical Hematology,
12th ed. Lippincott Williams & Wilkins, Philadelphia.
144. Wong SG, Card JW, Racz WJ. The role of mitochondrial injury in bromobenzene
and furosemide induced hepatotoxicity. Toxicol Lett. 2000; 116:171–81.
145. Woolbright BL, Antoine DJ, Jenkins RE, Bajt ML, Park BK, Jaeschke H. Plasma
biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during
obstructive cholestasis in mice. Toxicol Appl Pharmacol. 2013; 273:524–31.
146. Woolbright BL, Bridges BW, Dunn W, Olson JC, Weinman SA, Jaeschke H. Cell
Death and Prognosis of Mortality in Alcoholic Hepatitis Patients Using Plasma Keratin-
18. Gene Expr. 2017; 17:301–12.
147. Woolbright BL, Dorko K, Antoine DJ, Clarke JI, Gholami P, Li F, et al. Bile
acid-induced necrosis in primary human hepatocytes and in patients with obstructive
cholestasis. Toxicol Appl Pharmacol. 2015; 283:168–77.
148. Xie Y, McGill MR, Dorko K, Kumer SC, Schmitt TM, Forster J, et al.
Mechanisms of acetaminophen-induced cell death in primary human hepatocytes.
Toxicol Appl Pharmacol. 2014; 279:266–74.
149. Xu, J.J.; Henstock, P.V.; Dunn, M.C.; Smith, A.R.; Chabot, J.R.; de Graaf, D.
Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008,
105, 97–105.
150. Yang M, Antoine DJ, Weemhoff JL, Jenkins RE, Farhood A, Park BK, et al.
Biomarkers distinguish apoptotic and necrotic cell death during hepatic
ischemia/reperfusion injury in mice. Liver Transpl. 2014; 20:1372–82.
151. Zhang W, Parentau A, Greenly RL, et al. Effect of protein-calorie malnu- trition
on cytochromes P 450 and glutathione S-transferase. Eur. I. Drug Metab.Pharmacokinet.
1999;24:141-147.
152. Zimmerman, H.J. Hepatotoxicity: The Adverse Effects of Drugs and Other
Chemicals on the Liver, 2nd ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA,
1999.
153. Байкова ИЕ, Никитин ИГ. Лекарственные поражения печени. РМЖ.
2009;11(1):1-6.
154. Скрипник ИН. Медикаментозные гепатиты. Современные аспекты
диагностики и лечения. Consilium medicum. 2008;8.
155. Яковенко ЭП, Яковенко АВ, Иванов АН, и др. Лекарственно-
индуцированные поражения печени. Диагностика и лечение. Лечащий врач. 2011;
2:16-20.